Core Viewpoint - Fiserv, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its financial growth in 2025, particularly after revising its revenue guidance and subsequently reporting disappointing financial results [1][2][3]. Summary by Sections Company Overview - Fiserv, Inc. is a global payments and financial technology provider based in Milwaukee, Wisconsin [1]. Class Action Details - The class period for the lawsuit is from July 23, 2025, to October 29, 2025 [1]. - The lawsuit was filed on behalf of investors who purchased Fiserv shares during this period [1]. Allegations - In July 2025, Fiserv revised its 2025 guidance, lowering its organic revenue growth expectations due to a review of new initiatives and products [2]. - The company claimed that despite delays in certain initiatives, they were fundamentally sound [2]. - The complaint alleges that these representations were false and misleading [3]. Financial Impact - On October 29, 2025, Fiserv announced disappointing third-quarter results and acknowledged that its July guidance was based on assumptions that were difficult to achieve [3]. - Following this announcement, Fiserv's stock price dropped by $55.57 per share, or 44%, from $126.17 on October 28, 2025, to $70.60 on October 29, 2025 [3]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers by January 5, 2026 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless they recover losses [5].

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its business prospects during the class period surrounding its IPO on August 7, 2025 [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that the Offering Documents related to the IPO were negligently prepared, failing to disclose that Firefly overstated demand and growth prospects for its Spacecraft Solutions offerings [3]. - It is alleged that Firefly also overstated the operational readiness and commercial viability of its Alpha rocket program, which, when revealed, would likely have a material negative impact on the company [3]. - Following disappointing financial results reported on September 22, 2025, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [4]. - On September 29, 2025, Firefly disclosed a loss of the first stage of its Alpha Flight 7 rocket, leading to a further decline in stock price by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [4]. - As of the filing of the complaint, Firefly's stock price was significantly below the $45.00 per share offering price, indicating substantial damage to investors [4]. Group 2: Class Action Participation - Shareholders who purchased Firefly stock during the class period may be eligible to participate in the class action, with a deadline to submit papers to serve as lead plaintiff by January 12, 2026 [5]. - The lead plaintiff will represent other class members in directing the litigation, although participation is not required to be eligible for recovery [5].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc, alleging that the company misled investors regarding the value of its infant formula business, leading to significant financial losses for shareholders [1][2]. Allegations - The lawsuit claims that Perrigo failed to disclose critical issues with its infant formula business, including underinvestment in maintenance and operational improvements, the need for substantial capital expenditures beyond stated estimates, and significant manufacturing deficiencies [2]. - As a result of these undisclosed issues, Perrigo's financial results, including earnings and cash flow, were allegedly overstated [2]. Financial Impact - On November 5, 2025, Perrigo announced disappointing third-quarter financial results and slashed its fiscal year 2025 outlook, primarily due to challenges in the infant formula industry [3]. - The company also initiated a strategic review of its infant formula business, reassessing a previously announced investment of $240 million, which was deemed "less strategic" [3]. - Following this announcement, Perrigo's stock price dropped by $5.09, or 25.2%, closing at $15.10 per share on the same day [3].

Core Insights - Class actions have been initiated on behalf of stockholders of Skye Bioscience, Inc. and Perrigo Company plc, with deadlines for lead plaintiff petitions set for January 16, 2026 [1][3][7]. Perrigo Company plc - The class period for Perrigo is from February 27, 2023 to November 4, 2025, during which the company allegedly failed to disclose significant issues in its infant formula business acquired from Nestlé, including underinvestment and manufacturing deficiencies [3][4]. - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to challenges in the infant formula industry [4]. - Following the announcement, Perrigo's stock price dropped by $5.09, or 25.2%, closing at $15.10 per share [4]. Skye Bioscience, Inc. - The class period for Skye is from November 4, 2024 to October 3, 2025, during which the company allegedly made materially false statements regarding the effectiveness and prospects of its drug nimacimab [7]. - On October 6, 2025, Skye disclosed that the nimacimab monotherapy did not achieve its primary endpoint in a clinical study, resulting in a stock price decline of $2.85, or 60%, closing at $1.90 per share [7].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Perrigo Company plc, alleging that the company misled investors regarding its business operations and financial health during the specified Class Period from February 27, 2023, to November 4, 2025 [1][2]. Allegations - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance [3]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond its stated cost estimates to address issues within the infant formula business [3]. - The lawsuit points out significant manufacturing deficiencies in the facility related to Perrigo's infant formula business [3]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [3]. - The positive statements made by Perrigo regarding its business operations and prospects were claimed to be materially misleading and lacked a reasonable basis [3]. Class Action Participation - Investors who wish to serve as lead plaintiffs in the class action must file their motions with the court by January 16, 2026 [4]. - Participation in the case is not required to be eligible for recovery; investors can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its Inspire V Device, which is intended for the treatment of obstructive sleep apnea [1][3] - The class period for the lawsuit is from August 6, 2024, to August 4, 2025 [1] Allegations - The Inspire V Device was marketed as a groundbreaking product with significant revenue potential, but the launch was poorly received, leading to excess inventory and reluctance from providers to adopt the new treatment [3][4] - Key operational failures were cited, including incomplete training for treatment centers, lack of necessary IT systems, and unpreparedness for insurance claims processing and Medicare reimbursement [4] Financial Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an extended timeline due to undisclosed challenges, resulting in a drastic reduction of its 2025 earnings guidance by over 80%, from $2.20-$2.30 per share to $0.40-$0.50 per share [5] - Following this announcement, the stock price plummeted by $42.04, or more than 32%, from $129.95 to $87.91 per share, erasing $1.2 billion in market capitalization in a single day [5] - From a high of $216.71 per share on September 23, 2024, the stock price has decreased by $127.00, nearly 60%, resulting in billions lost in market capitalization [5]

Core Viewpoint - A class action has been filed against Primo Brands Corporation, alleging that the company misled investors regarding the merger with Blue Triton Brands and the subsequent integration challenges, leading to significant financial losses for shareholders [1][2][3][4]. Group 1: Merger and Integration Issues - The merger between Primo Water Corporation and Blue Triton Brands was announced on June 17, 2024, as a transformative all-stock transaction expected to enhance financial and operational capabilities [2]. - Despite positive statements from the company about the merger, the integration process faced significant challenges, including technology and service issues, which contradicted claims of a flawless execution [3]. - On November 6, 2025, it was revealed that the company was replacing its CEO and slashing its full-year 2025 net sales and adjusted EBITDA guidance, indicating that the integration was not proceeding as planned [4]. Group 2: Financial Impact - Following the announcement of leadership changes and reduced financial guidance, the stock price of Primo Brands fell by $8.20 per share, a decline of over 36%, resulting in a loss of $2.0 billion in market capitalization within two trading days [4]. Group 3: Class Action Participation - Shareholders who purchased stock during the specified periods may be eligible to participate in the class action, with a deadline to file as lead plaintiff by January 12, 2026 [5]. - The class action aims to represent shareholders in seeking recovery for losses incurred due to the alleged misleading statements and integration failures [5].

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Freeport-McMoran Inc. (NYSE: FCX) securities between February 15, 2022 and September 24, 2025. Freeport is a mining company. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Freeport-McMoran Inc. (FXC) Misled Investors ...

SAN DIEGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Company: Six Flags Entertainment Corporation (NYSE: FUN) is an amusement park operator. What is the class period? July 1, 2024, merger of Legacy Six Flags with Cedar Fair, L.P., and their subsidiaries and affiliates What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Six Flags common stock pursuant or traceable to the Company’s registration statement and prospectus ...

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit due to allegations of misleading investors about its growth prospects for fiscal year 2026, particularly following disappointing financial results that led to a significant drop in stock price [1][2][3]. Summary by Sections Company Overview - CarMax, Inc. is identified as the largest retailer of used vehicles in the United States [1]. Class Action Details - A class action was filed on behalf of investors who acquired CarMax securities between June 20, 2025, and September 24, 2025, alleging that the company misrepresented its growth potential [1][4]. Financial Performance - On September 25, 2025, CarMax reported disappointing financial results for the second quarter of fiscal year 2026, resulting in a stock price decline of $11.5 per share, or 20.07%, closing at $45.60 [2]. - The following day, the stock fell an additional 1.62%, closing at $44.86 [2]. Allegations of Misrepresentation - Plaintiffs claim that CarMax's growth was overstated, attributing earlier growth in fiscal year 2026 to temporary factors such as customer speculation regarding tariffs [3]. Next Steps for Investors - Shareholders interested in serving as lead plaintiffs must submit their papers by January 2, 2026, while those who do not wish to participate can remain as absent class members [4].